Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma.
Fiche publication
Date publication
janvier 2023
Journal
Histopathology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CRIBIER Bernard
Tous les auteurs :
Kervarrec T, Frouin E, Collin C, Tallet A, Tallegas M, Pissaloux D, Tirode F, Guyétant S, Samimi M, Gaboriaud P, Touzé A, Schrama D, Houben R, Tabareau-Delalande F, Neuhart A, de la Fouchardière A, Osio A, Cavelier-Balloy B, Laurent-Roussel S, Sohier P, Cyprien T, Balme B, Belzung F, Jullie ML, Cribier B, Battistella M, Macagno N
Lien Pubmed
Résumé
Recently, YAP1 fusion genes have been demonstrated in eccrine poroma and porocarcinoma, and the diagnostic use of YAP1 immunohistochemistry has been highlighted in this setting. In other organs, loss of YAP1 expression can reflect YAP1 rearrangement or transcriptional repression, notably through RB1 inactivation. In this context, our objective was to reevaluate the performance of YAP1 immunohistochemistry for the diagnosis of poroma and porocarcinoma.
Mots clés
Merkel, Rb-deficient squamous cell carcinoma, YAP1, porocarcinoma, poroma
Référence
Histopathology. 2023 01 31;: